159 related articles for article (PubMed ID: 33781701)
1. Continuous glucose monitoring indices predict poor FEV
Pallin M; Kumar S; Daley C; Dawadi S; Leong P; Carr E; Soldatos G
J Cyst Fibros; 2021 Sep; 20(5):785-791. PubMed ID: 33781701
[TBL] [Abstract][Full Text] [Related]
2. Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF.
Scully KJ; Brenner L; Martin K; Ruazol M; Sawicki GS; Uluer A; Neuringer I; Yonker LM; Sicilian L; Putman MS
Front Endocrinol (Lausanne); 2024; 15():1293709. PubMed ID: 38379863
[TBL] [Abstract][Full Text] [Related]
3. The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.
VanDevanter EJ; Heltshe SL; Skalland M; Lechtzin N; Nichols D; Goss CH
J Cyst Fibros; 2021 Nov; 20(6):932-936. PubMed ID: 33685776
[TBL] [Abstract][Full Text] [Related]
4. Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis.
Wagener JS; VanDevanter DR; Konstan MW; Pasta DJ; Millar SJ; Morgan WJ
Pediatr Pulmonol; 2020 Mar; 55(3):828-834. PubMed ID: 31746561
[TBL] [Abstract][Full Text] [Related]
5. Continuous glucose monitoring in a cystic fibrosis patient to predict pulmonary exacerbation?
Inman TB; Proudfoot JA; Lim M; Demeterco-Berggren C
J Cyst Fibros; 2017 Sep; 16(5):628-630. PubMed ID: 28625799
[TBL] [Abstract][Full Text] [Related]
6. Role of hyperglycemia in cystic fibrosis pulmonary exacerbations.
Merjaneh L; Sidhaye AR; Vu PT; Heltshe SL; Goss CH; Flume PA; Kelly A; Rosenfeld M
J Cyst Fibros; 2023 Sep; 22(5):868-874. PubMed ID: 37394317
[TBL] [Abstract][Full Text] [Related]
7. Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis.
Scully KJ; Sherwood JS; Martin K; Ruazol M; Marchetti P; Larkin M; Zheng H; Sawicki GS; Uluer A; Neuringer I; Yonker LM; Sicilian L; Wexler DJ; Putman MS
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1444-e1454. PubMed ID: 34850006
[TBL] [Abstract][Full Text] [Related]
8. Glycemic control and FEV
Okoniewski W; Hughan KS; Weiner GA; Weiner DJ; Forno E
J Cyst Fibros; 2020 May; 19(3):460-465. PubMed ID: 31980357
[TBL] [Abstract][Full Text] [Related]
9. Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score (CFRSD-CRISS).
Gold LS; Patrick DL; Hansen RN; Goss CH; Kessler L
J Cyst Fibros; 2019 Nov; 18(6):886-893. PubMed ID: 31126901
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE;
Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017
[TBL] [Abstract][Full Text] [Related]
11. Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients.
Leclercq A; Gauthier B; Rosner V; Weiss L; Moreau F; Constantinescu AA; Kessler R; Kessler L
J Cyst Fibros; 2014 Jul; 13(4):478-84. PubMed ID: 24359972
[TBL] [Abstract][Full Text] [Related]
12. The Role of Continuous Glucose Monitoring in Detecting Early Dysglycemia and Clinical Outcomes in Patients with Cystic Fibrosis.
Kirigin Biloš LS; Altabas V; Vukić Dugac A; Baretić M
Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541202
[TBL] [Abstract][Full Text] [Related]
13. Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations.
Heltshe SL; Russell R; VanDevanter DR; Sanders DB
J Cyst Fibros; 2023 Sep; 22(5):864-867. PubMed ID: 36803635
[TBL] [Abstract][Full Text] [Related]
14. Glycemic indices at night measured by CGM are predictive for a lower pulmonary function in adults but not in children with cystic fibrosis.
Declercq D; Helleputte S; Marchand S; Van Aken S; Van Braeckel E; Van Daele S; T'Sjoen G; Van Biervliet S; Lapauw B
J Cyst Fibros; 2023 Jan; 22(1):59-65. PubMed ID: 36068119
[TBL] [Abstract][Full Text] [Related]
15. Peak glucose during an oral glucose tolerance test is associated with future diabetes risk in adults with cystic fibrosis.
Bonhoure A; Potter KJ; Colomba J; Boudreau V; Bergeron C; Desjardins K; Carricart M; Tremblay F; Lavoie A; Rabasa-Lhoret R
Diabetologia; 2021 Jun; 64(6):1332-1341. PubMed ID: 33693987
[TBL] [Abstract][Full Text] [Related]
16. Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.
McElvaney OJ; Heltshe SL; Odem-Davis K; West NE; Sanders DB; Fogarty B; VanDevanter DR; Flume PA; Goss CH
Ann Am Thorac Soc; 2024 May; 21(5):716-726. PubMed ID: 38096105
[No Abstract] [Full Text] [Related]
17. Continuous glucose monitoring versus self-monitoring of blood glucose in the management of cystic fibrosis related diabetes: A systematic review and meta-analysis.
Kumar S; Soldatos G; Ranasinha S; Teede H; Pallin M
J Cyst Fibros; 2023 Jan; 22(1):39-49. PubMed ID: 35906171
[TBL] [Abstract][Full Text] [Related]
18. Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis.
VanDevanter DR; Heltshe SL; Hilliard JB; Konstan MW
J Cyst Fibros; 2021 Mar; 20(2):257-263. PubMed ID: 32505525
[TBL] [Abstract][Full Text] [Related]
19. Hypoglycemia is common in children with cystic fibrosis and seen predominantly in females.
Haliloglu B; Gokdemir Y; Atay Z; Abali S; Guran T; Karakoc F; Ersu R; Karadag B; Turan S; Bereket A
Pediatr Diabetes; 2017 Nov; 18(7):607-613. PubMed ID: 27873431
[TBL] [Abstract][Full Text] [Related]
20. Can continuous glucose monitoring predict cystic fibrosis-related diabetes and worse clinical outcome?
Zorron M; Marson FAL; Morcillo AM; Gonçalves AC; El Beck MS; Ribeiro JD; Ribeiro AF
J Bras Pneumol; 2022; 48(2):e20210307. PubMed ID: 35475864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
